DK0873319T3 - Quinazolinderivater - Google Patents

Quinazolinderivater

Info

Publication number
DK0873319T3
DK0873319T3 DK96941787T DK96941787T DK0873319T3 DK 0873319 T3 DK0873319 T3 DK 0873319T3 DK 96941787 T DK96941787 T DK 96941787T DK 96941787 T DK96941787 T DK 96941787T DK 0873319 T3 DK0873319 T3 DK 0873319T3
Authority
DK
Denmark
Prior art keywords
halogeno
trifluoromethyl
cyano
nitro
alkoxy
Prior art date
Application number
DK96941787T
Other languages
Danish (da)
English (en)
Inventor
Jean-Jacques Marcel Ze Lohmann
Laurent F A Zeneca-P Hennequin
Andrew Peter Zeneca Pha Thomas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26140602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0873319(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK0873319T3 publication Critical patent/DK0873319T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK96941787T 1995-12-18 1996-12-13 Quinazolinderivater DK0873319T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP95402846 1995-12-18
EP96402190 1996-10-15
PCT/GB1996/003075 WO1997022596A1 (fr) 1995-12-18 1996-12-13 Derives de quinazoline

Publications (1)

Publication Number Publication Date
DK0873319T3 true DK0873319T3 (da) 2001-10-22

Family

ID=26140602

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96941787T DK0873319T3 (da) 1995-12-18 1996-12-13 Quinazolinderivater

Country Status (29)

Country Link
US (4) US5962458A (fr)
EP (1) EP0873319B1 (fr)
JP (1) JP4291413B2 (fr)
KR (1) KR100530311B1 (fr)
CN (1) CN1133625C (fr)
AT (1) ATE203524T1 (fr)
AU (1) AU712370B2 (fr)
BR (1) BR9612043A (fr)
CA (1) CA2237005C (fr)
CZ (1) CZ291100B6 (fr)
DE (1) DE69614147T2 (fr)
DK (1) DK0873319T3 (fr)
ES (1) ES2162656T3 (fr)
GB (1) GB9624482D0 (fr)
GR (1) GR3036954T3 (fr)
HU (1) HUP9901243A3 (fr)
IL (1) IL124925A0 (fr)
MX (1) MX9804247A (fr)
MY (1) MY132405A (fr)
NO (1) NO311358B1 (fr)
NZ (1) NZ324007A (fr)
PL (1) PL192309B1 (fr)
PT (1) PT873319E (fr)
RU (1) RU2194701C2 (fr)
SI (1) SI0873319T1 (fr)
SK (1) SK282443B6 (fr)
TR (1) TR199801115T2 (fr)
TW (1) TW411274B (fr)
WO (1) WO1997022596A1 (fr)

Families Citing this family (543)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228871B1 (en) 1995-07-10 2001-05-08 Merck & Co., Inc. Angiogenesis inhibitors
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE237596T1 (de) 1996-02-13 2003-05-15 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
US6344459B1 (en) 1996-04-12 2002-02-05 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
BR9710002A (pt) 1996-06-27 1999-08-10 Janssen Pharmaceutica Nv N-[4-(heteroarilmetil)fenil]-heteroarilaminas
KR100567649B1 (ko) 1996-09-25 2006-04-05 아스트라제네카 유케이 리미티드 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JP2009007364A (ja) * 1996-10-15 2009-01-15 Astrazeneca Uk Ltd キナゾリン誘導体
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
FR2772763B1 (fr) * 1997-12-24 2004-01-23 Sod Conseils Rech Applic Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
IL139787A0 (en) 1998-06-02 2002-02-10 Osi Pharm Inc PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
US20040067227A1 (en) * 2001-11-02 2004-04-08 Goldstein Allan L. Inhibition or reversal of skin aging by actin-sequestering peptides
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
CZ303692B6 (cs) 1999-02-10 2013-03-13 Astrazeneca Ab Chinazolinové deriváty jako inhibitory angiogeneze
AU5003200A (en) 1999-05-14 2000-12-05 United States Of America As Represented By The Department Of Veterans Affairs, The Isolation and characterization of epidermal growth factor related protein
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
JP3686610B2 (ja) * 1999-06-21 2005-08-24 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 二環式複素環化合物、その化合物を含む医薬組成物、使用及び調製方法
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
SK3832002A3 (en) * 1999-09-21 2002-11-06 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
KR20020032612A (ko) * 1999-09-21 2002-05-03 다비드 에 질레스 퀴나졸린 유도체 및 그의 의약으로서의 용도
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
EE05330B1 (et) 1999-11-05 2010-08-16 Astrazeneca Ab Kinasoliini derivaadid kui VEGF-i inhibiitorid
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
AU4903201A (en) 1999-11-30 2001-07-03 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
HUP0300359A2 (hu) 2000-02-07 2003-06-28 Abbott Gmbh & Co. Kg. 2-Benzotiazolil-karbamid-származékok és protein kináz inhibitorként történő felhasználásuk és ezeket tartalmazó gyógyszerkészítmények
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
AUPQ592100A0 (en) * 2000-02-29 2000-03-23 Council Of The Queensland Institute Of Medical Research, The A method of treatment and prophylaxis
AU2001235804A1 (en) * 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
US20070021392A1 (en) * 2000-03-31 2007-01-25 Davis Peter D Divided dose therapies with vascular damaging activity
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
DK1274692T3 (da) * 2000-04-07 2006-10-30 Astrazeneca Ab Quinazolinforbindelser
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
MXPA03001332A (es) 2000-08-21 2004-07-08 Astrazeneca Ab Derivados de quinazolina.
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042058A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AU2001293233A1 (en) * 2000-09-01 2002-03-13 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
EP1650203B1 (fr) * 2000-09-11 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Procédé de pröparation des dérivés quinéolinone benzimidazol-2-yliques.
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
WO2002043735A1 (fr) * 2000-11-29 2002-06-06 Parker Hughes Institute Inhibiteurs d'agregation de plaquettes induite par la thrombine
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US7105530B2 (en) 2000-12-21 2006-09-12 Smithkline Beecham Corporation Pyrimidineamines as angiogenesis modulators
PL217921B1 (pl) 2001-01-05 2014-09-30 Amgen Fremont Inc Przeciwciało przeciw receptorowi insulinopodobnego czynnika wzrostu I, zawierająca go kompozycja farmaceutyczna, sposób jego wytwarzania, zastosowania, linia komórkowa, wyizolowana cząsteczka kwasu nukleinowego, wektor, komórka gospodarza oraz zwierzę transgeniczne
US20070050857A1 (en) * 2001-02-28 2007-03-01 Hayward Nick K Method of treatment and prophylaxis
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
WO2002092578A1 (fr) * 2001-05-14 2002-11-21 Astrazeneca Ab Derives de quinazoline
EP1408980A4 (fr) 2001-06-21 2004-10-20 Ariad Pharma Inc Nouvelles quinazolines et leur utilisation
WO2003000194A2 (fr) 2001-06-21 2003-01-03 Pfizer Inc. Derives bicycliques de pyridine et de pyrimidine utiles en tant qu'agents anticancereux
JP4836368B2 (ja) * 2001-08-30 2011-12-14 広栄化学工業株式会社 メチルヒドロキシアルキルピリジン類の製造方法
JP2005515176A (ja) * 2001-11-03 2005-05-26 アストラゼネカ アクチボラグ 抗腫瘍剤としてのキナゾリン誘導体
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2468673C (fr) * 2001-11-30 2011-01-25 Osi Pharmaceuticals, Inc. Composes specifiques inhibant les recepteurs a1 et a3 de l'adenosine, et applications desdits composes
AU2002357621A1 (en) * 2001-12-19 2003-06-30 Ube Industries, Ltd. Process for producing quinazolin-4-one and derivative thereof
ATE458483T1 (de) 2001-12-20 2010-03-15 Osi Pharm Inc Selektive pyrimidin-a2b-antagonistenverbindungen, ihre synthese und verwendung
CN1816551A (zh) * 2001-12-20 2006-08-09 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
WO2003064399A1 (fr) * 2002-01-28 2003-08-07 Ube Industries, Ltd. Procede de production de derive de quinazolin-4-one
CN101607958A (zh) * 2002-02-01 2009-12-23 阿斯特拉曾尼卡有限公司 喹唑啉化合物
EP1483268A2 (fr) 2002-03-01 2004-12-08 Pfizer Inc. Derives indolyl-uree de thienopyridines utilises comme agents antiangiogeniques, et leurs methodes d'utilisation
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US6936641B2 (en) * 2002-06-25 2005-08-30 Johnson & Johnson Vision Care, Inc. Macromer forming catalysts
EP2280003B1 (fr) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Procédé pour la préparation de modulateurs de kinases de type récepteur
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
AU2003257666A1 (en) 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
AU2003288899B2 (en) * 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
EP1539713B1 (fr) 2002-08-24 2007-12-19 Astrazeneca AB Derives de la pyrimidine utilises comme modulateurs d'activite du recepteur de chimiokine
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
BR0315756A (pt) * 2002-11-04 2005-09-06 Astrazeneca Ab Derivado de quinazolina ou um seu sal farmaceuticamente aceitável, processo para a preparação do mesmo, composição farmacêutica, uso do dito derivado ou de um seu sal farmaceuticamente aceitável, e, método para produzir um efeito anti-invasivo pela detenção e/ou pelo tratamento de doença de tumor sólido em um animal de sangue quente necessitando de tal tratamento
EP1565187A4 (fr) * 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic Procedes de traitement du cancer et procedes connexes
WO2004056806A1 (fr) 2002-12-19 2004-07-08 Pfizer Inc. Composes de 2-(1h-indazol-6-ylamino)-benzamides en tant qu'inhibiteurs de proteines kinases utiles pour le traitement de maladies ophtalmiques
PL223998B1 (pl) 2002-12-24 2016-11-30 Astrazeneca Ab N-(3-Fluorofenylo)-2-{3-[(7-{3-[etylo(2-hydroksyetylo)amino]propoksy}chinazolin-4-ylo)amino]-1H-pirazol-5-ilo} acetamid oraz jego kompozycja farmaceutyczna
US7223749B2 (en) * 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
RS53118B (en) 2003-02-26 2014-06-30 Sugen Inc. AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
GB0318423D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
CA2876822C (fr) 2003-08-27 2015-11-17 David Shima Polytherapie pour le traitement de troubles neovasculaires oculaires
JP2007504122A (ja) 2003-08-29 2007-03-01 ファイザー・インク 新規抗血管形成剤として有用なチエノピリジン−フェニルアセトアミドおよびその誘導体
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2005026151A1 (fr) * 2003-09-16 2005-03-24 Astrazeneca Ab Dérivés de quinozaline en tant qu'inhibiteurs de la tyrosine kinase
MXPA06002964A (es) 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
CA2538752C (fr) * 2003-09-19 2011-08-02 Astrazeneca Ab Derives de quinazoline
ATE353888T1 (de) * 2003-09-19 2007-03-15 Astrazeneca Ab Chinazolinderivate
WO2005030757A1 (fr) * 2003-09-25 2005-04-07 Astrazeneca Ab Derives de quinazoline
ES2651730T3 (es) 2003-09-26 2018-01-29 Exelixis, Inc. Moduladores c-Met y métodos de uso
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
CN1898240B (zh) 2003-10-15 2011-08-03 Osi制药公司 咪唑并吡嗪类酪氨酸激酶抑制剂
US20050137399A1 (en) * 2003-11-07 2005-06-23 Chiron Corporation Methods for synthesizing quinolinone compounds
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
JP4503022B2 (ja) 2003-12-23 2010-07-14 ファイザー・インク 新規キノリン誘導体
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
EP2305671A1 (fr) 2004-01-05 2011-04-06 AstraZeneca AB Dérivés de thiophène et thiazole comme inhibiteurs de CHK 1
CA2553423C (fr) * 2004-01-23 2012-03-20 Amgen Inc. Composes heterocycliques utilises dans le traitement du cancer et l'inhibition de l'angiogenese
TW200538120A (en) * 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
US7875624B2 (en) * 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
ATE433979T1 (de) 2004-04-02 2009-07-15 Osi Pharm Inc Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
CA2565812C (fr) 2004-05-06 2012-03-13 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
EP1756088A1 (fr) * 2004-06-04 2007-02-28 AstraZeneca AB Derives de quinazoline utilises comme tyrosine kinases du recepteur erbb
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
EP2322217A3 (fr) 2004-07-16 2011-09-28 Pfizer Products Inc. Traitement combiné pour malignités non hematologiques par anticorps anti-IGF-1R
MY139689A (en) 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
RS51362B (en) 2004-08-26 2011-02-28 Pfizer Inc. ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
DK1809624T3 (da) 2004-08-28 2014-01-20 Astrazeneca Ab Pyrimidinsulfonamidderivater som kemokinreceptor-modulatorer
EP1827434B1 (fr) 2004-11-30 2014-01-15 Amgen Inc. Heterocycles substitues et leurs procedes d'utilisation
WO2006064196A1 (fr) 2004-12-14 2006-06-22 Astrazeneca Ab Composes de pyrazolopyrimidine en tant qu’agents antitumoraux
CA2595610C (fr) 2004-12-21 2013-03-05 Astrazeneca Ab Anticorps diriges contre l'angiopoietine 2 et leurs utilisations
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
ATE526025T1 (de) * 2005-01-27 2011-10-15 Novartis Vaccines & Diagnostic Behandlung metastasierter tumore
ME02645B (fr) 2005-02-04 2012-04-30 Astrazeneca Ab Dérivés de pyrazolylaminopyridine employés en tant qu'inhibiteurs de kinase
BRPI0606905B1 (pt) * 2005-02-23 2021-06-01 Shionogi & Co., Ltd. Derivados de quinazolina tendo atividade inibitória de tirosina cinase e composição farmacêutica que os compreende
UY29398A1 (es) * 2005-02-26 2006-10-02 Astrazeneca Ab Derivados de quinazolinas, sussales farmacéuticamente aceptables, composiciones que los contienen, procedimientos de preparación y aplicacións.
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
WO2006105488A2 (fr) 2005-03-31 2006-10-05 Agensys, Inc. Anticorps et molecules correspondantes qui se fixent aux proteines 161p2f10b
AU2006238930B2 (en) 2005-04-26 2010-12-23 Pfizer Inc. P-cadherin antibodies
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
CN1858040B (zh) * 2005-05-08 2011-04-06 中国科学院上海药物研究所 5,8-二取代喹唑啉及其制备方法和用途
US8299081B2 (en) 2005-05-13 2012-10-30 Novartis Ag Methods for treating drug resistant cancer
RU2437878C2 (ru) 2005-05-17 2011-12-27 Новартис Аг Способы получения гетероциклических соединений
MY149960A (en) 2005-05-18 2013-11-15 Array Biopharma Inc 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
SG154451A1 (en) * 2005-05-23 2009-08-28 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1- yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
BRPI0613563A2 (pt) 2005-07-21 2012-01-17 Astrazeneca Ab novos derivados de piperidina
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
HUE025608T2 (en) 2005-09-07 2016-03-29 Amgen Fremont Inc Human monoclonal antibody against activin receptor-like kinase-1 (ALK-1)
JP2009508917A (ja) * 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 抗癌剤としてのキナゾリン誘導体
EP1928861B1 (fr) 2005-09-20 2010-11-17 AstraZeneca AB Composés de 4- (ih-indazol-5-yl-amino)-quinazoline utilisés comme inhibiteurs des recepteurs erbb des tyrosines kinases pour traiter le cancer
EP2372363A1 (fr) 2005-09-20 2011-10-05 OSI Pharmaceuticals, Inc. Marqueurs biologiques prédictifs d'une réaction anticancéreuse aux inhibiteurs kinase du récepteur du facteur de croissance 1 analogue à l'insuline
JPWO2007034881A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
US20090099216A1 (en) 2005-09-22 2009-04-16 Astrazeneca Aktiebolag A Corporation Of Sweden Novel adenine compound
US20090105212A1 (en) 2005-09-22 2009-04-23 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
WO2007034882A1 (fr) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. Nouveau compose d'adenine
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
JP5155171B2 (ja) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
EP2388259A1 (fr) 2005-10-28 2011-11-23 AstraZeneca AB Derives 4-(3-aminopyrazole)pyrimidine et leur utilisation en tant qu'inhibiteurs de tyrosine kinases dans le cadre d'un traitement anticancereux
CA2629244C (fr) 2005-11-11 2014-08-05 Boehringer Ingelheim International Gmbh Derives de quinazoline pour le traitement des affections cancereuses
PT2090575E (pt) 2005-11-15 2011-06-06 Array Biopharma Inc Inibidores de erbb
PT1957074E (pt) 2005-11-29 2014-06-25 Novartis Ag Formulações de quinolinonas
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
JP2009517451A (ja) * 2005-12-02 2009-04-30 アストラゼネカ アクチボラグ Ｅｒｂｂチロシンキナーゼの阻害剤として使用されるキナゾリン誘導体
WO2007063291A1 (fr) * 2005-12-02 2007-06-07 Astrazeneca Ab Dérivés de la quinazoline à substitution 4-anilino comme inhibiteurs de la tyrosine kinase
TW200730512A (en) 2005-12-12 2007-08-16 Astrazeneca Ab Novel compounds
KR101372690B1 (ko) 2005-12-13 2014-03-17 아스트라제네카 아베 인슐린 유사 성장 인자에 특이적인 결합 단백질 및 이의용도
ATE545637T1 (de) 2005-12-15 2012-03-15 Astrazeneca Ab Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
US20070231298A1 (en) * 2006-03-31 2007-10-04 Cell Genesys, Inc. Cytokine-expressing cancer immunotherapy combinations
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
MEP43308A (en) 2006-05-09 2011-02-10 Pfizer Prod Inc Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
US7741360B2 (en) 2006-05-26 2010-06-22 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
DE102006037478A1 (de) 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
US7902189B2 (en) 2006-08-23 2011-03-08 Astrazeneca Ab Compounds
SI2068880T1 (sl) * 2006-09-18 2012-08-31 Boehringer Ingelheim Int Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
CL2007003158A1 (es) 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
EP1921070A1 (fr) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
US7799954B2 (en) 2006-11-17 2010-09-21 Abraxis Bioscience, Llc Dicarbonyl derivatives and methods of use
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
MX2009006018A (es) 2006-12-19 2009-06-16 Astrazeneca Ab Derivados de quinuclidinol como antagonistas de receptores muscarinicos.
CL2008000191A1 (es) 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
KR20090116782A (ko) 2007-02-06 2009-11-11 베링거 인겔하임 인터내셔날 게엠베하 바이사이클릭 헤테로사이클, 당해 화합물을 함유하는 약물, 이의 용도 및 이의 제조방법
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
TW200902018A (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
JPWO2008114819A1 (ja) 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
DE102007025717A1 (de) 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
DE102007025718A1 (de) 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007038957A1 (de) 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
DE102007041115A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh Thiadiazinonderivate
WO2009033094A2 (fr) 2007-09-07 2009-03-12 Agensys, Inc. Anticorps et molécules apparentées qui se lient aux protéines 24p4c12
NZ584160A (en) 2007-10-04 2011-05-27 Astrazeneca Ab Steroidal [3,2-c] pyrazole compounds, with glucocorticoid activity
JP4705695B2 (ja) 2007-10-11 2011-06-22 アストラゼネカ アクチボラグ プロテインキナーゼｂ阻害剤としてのピロロ［２，３−ｄ］ピリミジン誘導体
SI2690101T1 (sl) 2007-12-19 2015-10-30 Genentech, Inc. 5-anilinoimidazopiridini in postopki za uporabo
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
MX343594B (es) 2007-12-21 2016-11-11 Medimmune Ltd Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
KR20100099185A (ko) 2007-12-21 2010-09-10 제넨테크, 인크. 아자인돌리진 및 이용 방법
WO2009091939A1 (fr) * 2008-01-18 2009-07-23 Osi Pharmaceuticals, Inc. Dérivés d'imidazopyrazinol pour le traitement des cancers
WO2009094216A1 (fr) * 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Dérivés de géfitinib
WO2009094210A1 (fr) * 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Dérivés de vandetanib
ME01461B (me) 2008-02-07 2014-04-20 Boehringer Ingelheim Int Spirociklični heterocikli, ljekovi koji sadrže navedeno jedinjenje, njihova primjena i postupak za njihovu proizvodnju.
CA2712990C (fr) 2008-02-28 2016-09-27 Bayard R. Huck Composes de benzonaphthyridinyl comme inhibiteurs de proteines kinases et son utilisation
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
WO2009138781A1 (fr) 2008-05-13 2009-11-19 Astrazeneca Ab Sel de fumarate de 4-(3-chloro-2-fluoroanilino)-7-méthoxy-6-{[1-(n-méthylcarbamoylméthyl)pipéridin-4-yl]oxy}quinazoline
JP2011520970A (ja) * 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
PT2297106E (pt) 2008-05-27 2014-09-29 Astrazeneca Ab Derivados de fenoxipiridinilamida e seu uso no tratamento de estados de doença mediados por pde4
DE102008025750A1 (de) 2008-05-29 2009-12-03 Merck Patent Gmbh Dihydropyrazolderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008029734A1 (de) 2008-06-23 2009-12-24 Merck Patent Gmbh Thiazolyl-piperidinderivate
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
CA2733153C (fr) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Heterocycles a substitution cyclohexyloxy, medicaments contenant ces composes, leur utilisation et procedes pour les preparer
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
US8192738B2 (en) 2008-09-19 2012-06-05 Medimmune, Llc Targeted antibodies directed to DLL4
CA2737597C (fr) 2008-10-16 2017-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anticorps entierement humains diriges contre un antigene associe au melanome de masse moleculaire elevee et leurs utilisations
DE102008052943A1 (de) 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
WO2010067102A1 (fr) 2008-12-09 2010-06-17 Astrazeneca Ab Dérivés de diazaspiro[5.5]undécane et composés associés utilisés comme antagonistes des récepteurs muscariniques et agonistes des récepteurs bêta adrénergiques dans le traitement des affections pulmonaires
EP2373326B1 (fr) 2008-12-11 2016-03-09 Axcentua Pharmaceutucals AB Formes cristallines de la génistéine
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
US20100152197A1 (en) 2008-12-15 2010-06-17 Astrazeneca Ab (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
AU2009333653B2 (en) 2008-12-17 2015-09-10 Merck Patent Gmbh C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
DE102008063667A1 (de) 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
US8853391B2 (en) 2008-12-18 2014-10-07 Merck Patent Gmbh Tricyclic azaindoles
JP2012513194A (ja) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ α５β１に向けられた標的結合剤およびその使用
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
DE102008062826A1 (de) 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
DE102009003954A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate
DE102009003975A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
DE102009004061A1 (de) 2009-01-08 2010-07-15 Merck Patent Gmbh Pyridazinonderivate
KR20210151988A (ko) 2009-01-16 2021-12-14 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
MX368362B (es) 2009-02-05 2019-09-30 Immunogen Inc Derivados novedosos de benzodiacepina.
WO2010089580A1 (fr) 2009-02-06 2010-08-12 Astrazeneca Ab Utilisation d'un inhibiteur de mct1 de traitement du cancer exprimant mct1 sur mct4
JP2012517426A (ja) 2009-02-09 2012-08-02 アステックス ファーマシューティカルズ インコーポレイテッド ピロロピリミジニルａｘｌキナーゼ阻害剤
EP2396333B1 (fr) 2009-02-10 2013-07-03 AstraZeneca AB Dérivés de triazolo[4,3-b]pyridazine et leurs utilisations contre le cancer de la prostate
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010099138A2 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
US20100222381A1 (en) 2009-02-27 2010-09-02 Hariprasad Vankayalapati Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
WO2010099363A1 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
EP2401613A2 (fr) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
GB0905127D0 (en) 2009-03-25 2009-05-06 Pharminox Ltd Novel prodrugs
UY32520A (es) 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
MX2011011025A (es) 2009-04-20 2011-11-02 Osi Pharmaceuticals Llc Preparacion de c-piracin-metilaminas.
WO2010129740A1 (fr) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Utilisation d'osi-906 dans le traitement du carcinome adrénocortical
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
ES2731901T3 (es) 2009-07-06 2019-11-19 Boehringer Ingelheim Int Proceso para el secado de BIBW2992, de sus sales y de formulaciones farmacéuticas sólidas que comprenden este ingrediente activo
WO2011008696A2 (fr) 2009-07-13 2011-01-20 Genentech, Inc. Procédés de diagnostic et compositions pour traitement d'un cancer
WO2011014726A1 (fr) 2009-07-31 2011-02-03 Osi Pharmaceuticals, Inc. Polythérapie par inhibiteur de mtor et inhibiteur de l’angiogenèse
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2772194A1 (fr) 2009-09-01 2011-03-10 Pfizer Inc. Derives de benzimidazole
CN102597776A (zh) 2009-09-11 2012-07-18 霍夫曼-拉罗奇有限公司 鉴定响应抗癌剂的可能性升高的患者的方法
BR112012005670A2 (pt) 2009-09-17 2017-01-10 Hoffmann La Roche ''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso
DE102009043260A1 (de) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
JP2013506649A (ja) 2009-10-02 2013-02-28 アストラゼネカ・アクチエボラーグ 好中球エラスターゼの阻害剤として使用する２−ピリドン化合物
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011048409A1 (fr) 2009-10-20 2011-04-28 Astrazeneca Ab Dérivés d'amine cyclique ayant une activité agoniste de récepteur adrénergique bêta-2 et antagoniste de récepteur muscarinique
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
CA2779073C (fr) 2009-10-30 2017-10-24 Domain Therapeutics Nouveaux derives d'oximes et leur utilisation comme modulateurs allosteriques de recepteurs metabotropiques du glutamate
BR112012011518B8 (pt) 2009-11-18 2023-01-10 Astrazeneca Ab Compostos, composição farmacêutica, kit e usos de um composto
PL3279215T3 (pl) 2009-11-24 2020-06-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
EP2507237A1 (fr) 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines agissant par l'intermédiaire des récepteurs de type toll (tlr)
MX2012006776A (es) 2009-12-14 2012-10-05 Merck Patent Gmbh Inhibidores de la esfingosina quinasa.
DE102009058280A1 (de) 2009-12-14 2011-06-16 Merck Patent Gmbh Thiazolderivate
WO2011073521A1 (fr) 2009-12-15 2011-06-23 Petri Salven Méthodes pour l'enrichissement de cellules progénitrices endothéliales adultes et leurs utilisations
MX2012006962A (es) 2009-12-17 2012-07-17 Merck Patent Gmbh Inhibidores de la esfingosina quinasa.
CA2786465C (fr) 2010-01-15 2018-09-25 Suzhou Neupharma Co., Ltd. Derives de bufaline destines au traitement du cancer
BR112012017884A2 (pt) 2010-01-19 2019-09-24 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, derivado de pirazina, métodos para o tratamento ou prevenção, para promoção óssea, e, para tratar lesões ósseas em cânceres
WO2011095807A1 (fr) 2010-02-07 2011-08-11 Astrazeneca Ab Combinaisons d'inhibiteurs de mek et de hh
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
RS55487B2 (sr) 2010-02-12 2024-06-28 Pfizer Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109572A2 (fr) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
WO2011114148A1 (fr) 2010-03-17 2011-09-22 Astrazeneca Ab Dérivés de 4h-[1,2,4]triazolo[5,1-b]pyrimidin-7-one à titre d'antagonistes des récepteurs ccr2b
WO2011153224A2 (fr) 2010-06-02 2011-12-08 Genentech, Inc. Procédés diagnostiques et compositions de traitement du cancer
WO2011154677A1 (fr) 2010-06-09 2011-12-15 Astrazeneca Ab Composés n-[1-cyano-2-(phényl)éthyl] 1-aminocycloalk-1-ylcarboxamide substitués - 760
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
CN104689314B (zh) 2010-06-16 2018-02-02 高等教育联邦系统-匹兹堡大学 内质蛋白的抗体及其用途
CA2804246A1 (fr) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Methode d'identification d'un patient presentant une probabilite accrue de repondre a un traitement anticancereux
CN103180738A (zh) 2010-07-19 2013-06-26 霍夫曼-拉罗奇有限公司 鉴定响应抗癌疗法的可能性升高的患者的方法
CN103261225A (zh) 2010-07-23 2013-08-21 波士顿大学董事会 作为用于抑制病理性血管生成和肿瘤细胞侵袭力的治疗剂以及用于分子成像和靶向递送的抗DEspR抑制剂
UY33539A (es) 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
DE102010034699A1 (de) 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
US9018197B2 (en) 2010-08-28 2015-04-28 Suzhou Neupharma Co. Ltd. Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use
WO2012042421A1 (fr) 2010-09-29 2012-04-05 Pfizer Inc. Procédé de traitement de la croissance cellulaire anormale
GB201016442D0 (en) 2010-09-30 2010-11-17 Pharminox Ltd Novel acridine derivatives
WO2012052948A1 (fr) 2010-10-20 2012-04-26 Pfizer Inc. Dérivés de pyridine-2 en tant que modulateurs des récepteurs smoothened
DE102010048800A1 (de) 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
DE102010049595A1 (de) 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
WO2012067269A1 (fr) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Composés aminoalcoxyphényle et leur utilisation dans le traitement de maladies
WO2012066336A1 (fr) 2010-11-19 2012-05-24 Astrazeneca Ab Composés de benzylamine à titre d'agonistes du récepteur toll-like 7
JP2013542916A (ja) 2010-11-19 2013-11-28 大日本住友製薬株式会社 環状アミド化合物および疾患の処置におけるその使用
WO2012066335A1 (fr) 2010-11-19 2012-05-24 Astrazeneca Ab Composés phénol en tant qu'agonistes du récepteur 7 de type toll
CN103370317B (zh) 2010-12-16 2015-10-07 阿斯利康(瑞典)有限公司 可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物
ES2627433T3 (es) 2010-12-17 2017-07-28 Sumitomo Dainippon Pharma Co., Ltd. Derivados de purina
KR20140003467A (ko) 2010-12-20 2014-01-09 메디뮨 리미티드 항il-18 항체 및 그의 용도
EP3453714B1 (fr) 2011-02-02 2020-11-04 Suzhou Neupharma Co., Ltd Des dérivés 3-carbonates and 3-carbamates des cardenolides et des bufadienolides pour le traitement du cancer aussi bien que des compositions les contenant
EP3666289A1 (fr) 2011-02-15 2020-06-17 ImmunoGen, Inc. Dérivés de benzodiazépine cytotoxique
US9174946B2 (en) 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
CA2827171C (fr) 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Inhibiteurs de fak
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
WO2012142164A1 (fr) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps monoclonaux humains qui se lient aux facteurs de croissance insulinomimétique (igf) de type i et ii
US8530470B2 (en) 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
TR201905909T4 (tr) 2011-04-19 2019-05-21 Pfizer Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2012175991A1 (fr) 2011-06-24 2012-12-27 Pharminox Limited Composés pentacycliques fusionnés anti-prolifératifs
WO2013003697A1 (fr) 2011-06-30 2013-01-03 Trustees Of Boston University Méthode de régulation de croissance tumorale, d'angiogenèse et de métastase à l'aide du récepteur 1 riche en proline et contenant une immunoglobuline (igpr-1)
MY180039A (en) 2011-07-12 2020-11-20 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
DK2734205T3 (en) 2011-07-21 2018-06-14 Tolero Pharmaceuticals Inc Heterocyclic Protein Kinase Inhibitors
DK3686194T3 (da) 2011-07-27 2021-11-22 Astrazeneca Ab 2-(2,4,5-substitueret-anilino)pyrimidinforbindelser
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
CN104053442B (zh) 2011-08-26 2017-06-23 润新生物公司 某些化学实体、组合物及方法
CN104080335B (zh) 2011-09-01 2017-06-09 钱向平 某些化学实体、组合物及方法
JP6093768B2 (ja) 2011-09-14 2017-03-08 ニューファーマ， インコーポレイテッド 特定の化学的実体、組成物、および方法
EP2757885B1 (fr) 2011-09-21 2017-03-15 Neupharma, Inc. Entités chimiques, compositions, et procédés spécifiques
MX2014003501A (es) 2011-09-22 2014-07-22 Pfizer Derivados de pirrolopirimidina y purina.
EP2760458B1 (fr) 2011-09-29 2017-06-14 The University of Liverpool Prévention et/ou traitement du cancer et/ou d'une métastase cancéreuse
WO2013049701A1 (fr) 2011-09-30 2013-04-04 Neupharma, Inc. Certaines entités chimiques, compositions et procédés
EP3275902A1 (fr) 2011-10-04 2018-01-31 IGEM Therapeutics Limited Anticorps ige anti-hmw-maa
MX2014005570A (es) 2011-11-08 2014-05-30 Pfizer El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios.
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
WO2013112950A2 (fr) 2012-01-25 2013-08-01 Neupharma, Inc. Entités chimiques particulières, compositions et procédés
KR20140117636A (ko) 2012-01-28 2014-10-07 메르크 파텐트 게엠베하 트리아졸로[4,5-ｄ]피리미딘 유도체
AU2013218354B2 (en) 2012-02-09 2017-01-19 Merck Patent Gmbh Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as TBK1 and IKK inhibitors
AU2013218357B2 (en) 2012-02-09 2017-01-05 Merck Patent Gmbh Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors
JP6097770B2 (ja) 2012-02-21 2017-03-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ フロピリジン誘導体
US9073944B2 (en) 2012-02-21 2015-07-07 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
WO2013124026A1 (fr) 2012-02-21 2013-08-29 Merck Patent Gmbh 2-amino-[1,2,4]triazolo[1,5-a]pyrazines substituées en 8ème position en tant qu'inhibiteurs de la tyrosine kinase syk et en tant qu'inhibiteurs de la sérine kinase gcn2
CA2866450C (fr) 2012-03-07 2020-02-18 Merck Patent Gmbh Derives de triazolopyrazine
AU2013242492B2 (en) 2012-03-28 2016-12-15 Merck Patent Gmbh Bicyclic pyrazinone derivatives
WO2013144532A1 (fr) 2012-03-30 2013-10-03 Astrazeneca Ab Dérivés de pyrimidine 3-cyano-5-arylamino -7-cycloalkylaminopyrrolo [1, 5-a] et leurs utilisations comme agents antitumoraux
CN104245738B (zh) 2012-04-05 2018-02-02 弗·哈夫曼-拉罗切有限公司 针对人tweak和人il17的双特异性抗体及其用途
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
EP2852285B1 (fr) 2012-04-29 2018-08-08 Neupharma, Inc. Dérivés bufadiènolides substitués en position 3 par un groupement amine hétérocyclique pour le traitement de cancer
CN104271580B (zh) 2012-05-04 2017-02-22 默克专利股份公司 吡咯并三嗪酮衍生物
EP3505534A1 (fr) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Anticorps comprenant des résidus d'acides aminés non endogènes spécifiques d'un site, leurs procédés de préparation et leurs procédés d'utilisation
GB201211021D0 (en) 2012-06-21 2012-08-01 Cancer Rec Tech Ltd Pharmaceutically active compounds
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
WO2014015934A1 (fr) 2012-07-24 2014-01-30 Merck Patent Gmbh Dérivés d'hydroxystatine pour le traitement de l'arthrose
AU2013301865B2 (en) 2012-08-07 2017-08-17 Merck Patent Gmbh Pyridopyrimidine derivatives as protein kinase inhibitors
JP6247294B2 (ja) 2012-08-08 2017-12-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ （アザ−）イソキノリノン誘導体
CN104736533B (zh) 2012-08-17 2016-12-07 癌症治疗合作研究中心有限公司 Vegfr3抑制剂
WO2014031566A1 (fr) 2012-08-22 2014-02-27 Immunogen, Inc. Dérivés de benzodiazépine cytotoxique
SI2890402T1 (sl) 2012-08-31 2019-07-31 Sutro Biopharma, Inc. Modificirane aminokisline vsebujoče acido skupino
WO2014041349A1 (fr) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Pyrimidines ou pyridazines tétrahydropyran-4-yléthylamino- ou tétrahydropyranyl-4-éthyloxy utiles comme inhibiteurs de l'isoprényl-cystéine-carboxy-méthyl-transférase
CN104812389B (zh) 2012-09-24 2020-07-17 润新生物公司 某些化学实体、组合物及方法
JP6276769B2 (ja) 2012-09-26 2018-02-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｐａｒｐインヒビターとしてのキナゾリノン誘導体
JP6348115B2 (ja) 2012-10-26 2018-06-27 ザ ユニバーシティー オブ クイーンズランド がん療法のためのエンドサイトーシス阻害剤および抗体の使用
WO2014066955A1 (fr) 2012-11-05 2014-05-08 Lindley Robyn Alice Procédés de détermination de la cause d'une mutagenèse somatique
WO2014075077A1 (fr) 2012-11-12 2014-05-15 Neupharma, Inc. Certaines entités chimiques, compositions et certains procédés
ES2608355T3 (es) 2012-11-16 2017-04-10 Merck Patent Gmbh Derivados de 3-aminociclopentanocarboxamida.
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
DK2951177T3 (en) 2013-01-31 2018-06-14 Neomed Inst IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF
US9663475B2 (en) 2013-02-25 2017-05-30 Merck Patent Gmbh 2 amino-3,4-dihydrcquinazoline derivatives and the use thereof as cathepsin D inhibitors
WO2014134486A2 (fr) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques
EP3566750A3 (fr) 2013-02-28 2020-04-08 ImmunoGen, Inc. Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
JP6409007B2 (ja) 2013-03-05 2018-10-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗癌剤としての９−（アリールまたはヘテロアリール）−２−（ピラゾリル、ピロリジニルまたはシクロペンチル）アミノプリン誘導体
CA2905993C (fr) 2013-03-14 2022-12-06 Tolero Pharmaceuticals, Inc. Derives de 4-amino-pyrimidinyle-2-amino-phenyle substitues et compositions pharmaceutiques a base de ceux-ci en tant qu'inhibiteurs dejak2 et d'alk2
CN105142648A (zh) 2013-03-15 2015-12-09 玛格塞蒂克斯公司 用于癌症的镁组合物及其用途
WO2014161570A1 (fr) 2013-04-03 2014-10-09 Roche Glycart Ag Anticorps dirigés contre l'il17 humaine et ses utilisations
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
WO2014194030A2 (fr) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
US20160115146A1 (en) 2013-06-07 2016-04-28 Universite Catholique De Louvain 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
CA2916533C (fr) 2013-06-25 2022-12-20 University Of Canberra Procedes et compositions de modulation des cellules souches cancereuses
EP3019522B1 (fr) 2013-07-10 2017-12-13 Sutro Biopharma, Inc. Anticorps comprenant plusieurs résidus d'acides aminés non naturels site-spécifiques, des procédés permettant leur préparation et leurs méthodes d'utilisation
JP6559132B2 (ja) 2013-08-23 2019-08-14 ニューファーマ， インコーポレイテッド ある特定の化学的実体、組成物および方法
WO2015039187A1 (fr) 2013-09-18 2015-03-26 University Of Canberra Modulation de cellules souches
US20160298197A1 (en) 2013-10-01 2016-10-13 Queensland University Of Technology Kits and methods for diagnosis, screening, treatment and disease monitoring
US20150104392A1 (en) 2013-10-04 2015-04-16 Aptose Biosciences Inc. Compositions, biomarkers and their use in the treatment of cancer
EP3055298B1 (fr) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
GB201321146D0 (en) * 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN104829542B (zh) * 2014-02-10 2018-02-02 中国科学院上海药物研究所 苯胺嘧啶类化合物、其制备方法和医药用途
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
US10501805B2 (en) 2014-04-04 2019-12-10 Crown Bioscience, Inc. (Taicang) Methods for determining responsiveness to MEK/ERK inhibitors
WO2015155624A1 (fr) 2014-04-10 2015-10-15 Pfizer Inc. Dérivés de dihydropyrrolopyrimidine
CR20160497A (es) 2014-04-30 2016-12-20 Pfizer Derivados de diheterociclo enlazado a cicloalquilo
WO2016001789A1 (fr) 2014-06-30 2016-01-07 Pfizer Inc. Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer
ES2848857T3 (es) 2014-07-31 2021-08-12 Us Gov Health & Human Services Anticuerpos monoclonales humanos contra EphA4 y su uso
CN105330653A (zh) * 2014-08-11 2016-02-17 石药集团中奇制药技术（石家庄）有限公司 喹唑啉衍生物
US10485772B2 (en) 2014-08-25 2019-11-26 EpiAxis Therapeutics Pty Ltd. Compositions for modulating cancer stem cells and uses therefor
WO2016077881A1 (fr) 2014-11-17 2016-05-26 The University Of Queensland Biomarqueurs de glycoprotéines pour l'adénocarcinome de l'œsophage et l'œsophage de barrett et leurs utilisations
WO2016097918A1 (fr) 2014-12-18 2016-06-23 Pfizer Inc. Dérivés de pyrimidine et de triazine, et leur utilisation comme inhibiteurs d'axl
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
EP3270694A4 (fr) 2015-02-17 2018-09-05 Neupharma, Inc. Entités chimiques, compositions et méthodes particulières
RU2717829C2 (ru) 2015-04-20 2020-03-26 Толеро Фармасьютикалз, Инк. Прогнозирование ответа на альвоцидиб с помощью анализа профиля митохондрий
CN107709344B (zh) 2015-05-01 2022-07-15 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的核苷类似物
CA2985804A1 (fr) 2015-05-18 2016-11-24 Tolero Pharmaceuticals, Inc. Promedicaments de l'alvocidib a biodisponibilite augmentee
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
WO2017009751A1 (fr) 2015-07-15 2017-01-19 Pfizer Inc. Dérivés de pyrimidine
WO2017024073A1 (fr) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Thérapies combinatoires pour le traitement du cancer
CN108349964B (zh) 2015-08-04 2021-06-01 常州千红生化制药股份有限公司 N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物
AU2016310415B2 (en) 2015-08-26 2022-04-21 Gmdx Co Pty Ltd Methods of detecting cancer recurrence
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519568D0 (en) 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US20180371551A1 (en) 2015-12-03 2018-12-27 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
AU2016377398B2 (en) 2015-12-23 2022-10-13 Repluca Pty Ltd Nucleic acid oligomers and uses therefor
RU2018130757A (ru) 2016-01-27 2020-02-27 Сутро Биофарма, Инк. Конъюгаты антитела к cd74, композиции, содержащие конъюгаты антитела к cd74, и способы использования конъюгатов антитела к cd74
EP3411061A4 (fr) 2016-02-01 2019-07-10 University of Canberra Composés protéiques et leurs utilisations
GB201604182D0 (en) 2016-03-11 2016-04-27 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN108884084A (zh) 2016-03-21 2018-11-23 阿斯利康(瑞典)有限公司 噌啉-4-胺化合物及其在治疗癌症中的用途
EP3440079A1 (fr) 2016-04-07 2019-02-13 Astrazeneca AB Oxyde de n,n-diméthyl-3-[[5-(3-méthyl-2-oxo-1-tétrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine utilisé comme modulateur de la protéine kinase atm (ataxia telangiectasia mutated) pour traiter le cancer
DK3442535T3 (da) 2016-04-15 2022-09-05 Cancer Research Tech Ltd Heterocykliske stoffer som as ret-kinase-hæmmere
GB2554333A (en) 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
GB201608227D0 (en) 2016-05-11 2016-06-22 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
IL264397B2 (en) 2016-07-29 2024-04-01 Rapt Therapeutics Inc Receptor regulators of chemokines and their uses
CA3033370A1 (fr) 2016-08-15 2018-02-22 Neupharma, Inc. Entites chimiques, compositions et methodes particulieres
CA3035081A1 (fr) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition et methodes de traitement des dereglements des lymphocytes b
CN110036006B (zh) 2016-09-22 2022-12-13 癌症研究科技有限公司 嘧啶酮衍生物的制备和用途
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
ES2906439T3 (es) 2016-12-05 2022-04-18 Apros Therapeutics Inc Compuestos de pirimidina que contienen grupos ácidos
AU2017379847B2 (en) 2016-12-19 2022-05-26 Sumitomo Pharma Oncology, Inc. Profiling peptides and methods for sensitivity profiling
MA47079B1 (fr) 2016-12-20 2021-05-31 Astrazeneca Ab Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
US11111245B2 (en) 2017-02-01 2021-09-07 Aucentra Therapeutics Pty Ltd Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
US10703723B2 (en) 2017-03-09 2020-07-07 Truly Translational Sweden Ab Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
JOP20190209A1 (ar) 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
GB201704325D0 (en) 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
CN108864079B (zh) 2017-05-15 2021-04-09 深圳福沃药业有限公司 一种三嗪化合物及其药学上可接受的盐
CA3065005A1 (fr) 2017-05-26 2018-11-29 Cancer Research Technology Limited Inhibiteurs de bcl6 derives de benzimidazolone
EP3630749B9 (fr) 2017-05-26 2024-05-29 Cancer Research Technology Limited Dérivés de la 2-quinolone en tant qu'inhibiteurs du récepteur bcl6
EP3630188B1 (fr) 2017-05-31 2021-08-25 Amplio Pharma AB Composition pharmaceutique comprenant une association de méthotrexate et de novobiocine, et utilisation de ladite composition en thérapie
US11319304B2 (en) * 2017-06-28 2022-05-03 Vanderbilt University Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
AU2017422200B2 (en) 2017-07-05 2022-11-24 E.P.O.S Iasis Research And Development Limited Multifunctional conjugates
US20200207859A1 (en) 2017-07-26 2020-07-02 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
US11186592B2 (en) 2017-08-01 2021-11-30 Merck Patent Gmbh Thiazolopyridine derivatives as adenosine receptor antagonists
WO2019034890A1 (fr) 2017-08-18 2019-02-21 Cancer Research Technology Limited Composés pyrrolo[2,3-b]pyridine et leur utilisation dans le traitement du cancer
SG11202001340VA (en) 2017-08-21 2020-03-30 Merck Patent Gmbh Quinoxaline derivatives as adenosine receptor antagonists
JP7287952B2 (ja) 2017-08-21 2023-06-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング アデノシン受容体アンタゴニストとしてのベンズイミダゾール誘導体
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
EP3684814A1 (fr) 2017-09-18 2020-07-29 Sutro Biopharma, Inc. Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations
CN111344293A (zh) 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
TWI702205B (zh) 2017-10-06 2020-08-21 俄羅斯聯邦商拜奧卡德聯合股份公司 表皮生長因子受體抑制劑
WO2019075367A1 (fr) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. Activateurs de pkm2 en combinaison avec des espèces réactives de l'oxygène pour le traitement du cancer
TWI838350B (zh) 2017-11-06 2024-04-11 美商瑞佩特治療公司 抗癌劑
EP3489222A1 (fr) 2017-11-23 2019-05-29 medac Gesellschaft für klinische Spezialpräparate mbH Sels de sulfasalazine, procédés de production et utilisations
FI3488868T3 (fi) 2017-11-23 2023-10-20 Medac Ges Fuer Klinische Spezialpraeparate Mbh Suun kautta annettava sulfasalatsiinia ja/tai sulfasalatsiinin orgaanista suolaa sisältävä farmaseuttinen koostumus, valmistusmenetelmä ja käyttö
CA3087805A1 (fr) 2018-01-15 2019-07-18 Aucentra Holdings Pty Ltd Derives de 5-(pyrimidin-4-yl)thiazol-2-yl uree en tant qu'agents therapeutiques
GB201801128D0 (en) 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
BR112020015056A2 (pt) 2018-01-26 2020-12-08 Rapt Therapeutics, Inc. Moduladores de receptor de quimiocina e usos dos mesmos
EP3749310A4 (fr) 2018-02-08 2021-08-18 Neupharma, Inc. Entités chimiques, compositions et méthodes particulières
WO2019175093A1 (fr) 2018-03-12 2019-09-19 Astrazeneca Ab Procédé de traitement du cancer du poumon
ES2939776T3 (es) 2018-04-13 2023-04-26 Cancer Research Tech Ltd Inhibidores de BCL6
MX2020011344A (es) 2018-04-27 2021-02-09 Spruce Biosciences Inc Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
GB201809102D0 (en) 2018-06-04 2018-07-18 Univ Oxford Innovation Ltd Compounds
CN112513031A (zh) 2018-06-04 2021-03-16 阿普罗斯治疗公司 可用于治疗与tlr7调节相关的疾病的含酸性基团的嘧啶化合物
EP3802544A1 (fr) 2018-06-05 2021-04-14 RAPT Therapeutics, Inc. Composés de pyrazolo-pyrimidin-amino-cycloalkyle et leurs utilisations thérapeutiques
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
MX2021000977A (es) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
WO2020060944A1 (fr) 2018-09-17 2020-03-26 Sutro Biopharma, Inc. Polythérapies avec des conjugués d'anticorps anti-récepteur du folate
FI3853220T3 (fi) 2018-09-18 2024-02-22 Hoffmann La Roche Kinatsoliinijohdannaisia antitumoraalisina aineina
WO2020068600A1 (fr) 2018-09-24 2020-04-02 Rapt Therapeutics, Inc. Modulateurs de la protéase 7 de traitement spécifique de l'ubiquitine (usp7) et leurs utilisations
JP7473544B2 (ja) 2018-10-25 2024-04-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング アデノシン受容体アンタゴニストとしての５－アザインダゾール誘導体
BR112021007727A2 (pt) 2018-10-25 2021-07-27 Merck Patent Gmbh derivados de 5-azaindazol como antagonistas receptores de adenosina
GB201819126D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
CN118530991A (zh) 2018-12-25 2024-08-23 中国医学科学院基础医学研究所 炎性相关疾病防治的小rna药物及其组合
AR117844A1 (es) 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US11033547B2 (en) 2019-03-07 2021-06-15 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as SHP2 antagonists
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
AU2020245437A1 (en) 2019-03-22 2021-09-30 Sumitomo Pharma Oncology, Inc. Compositions comprising PKM2 modulators and methods of treatment using the same
CN111747950B (zh) 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
US20230085408A1 (en) 2019-04-05 2023-03-16 STORM Therapeutics Ltd. Mettl3 inhibitory compounds
CA3127475A1 (fr) 2019-04-08 2020-10-15 Merck Patent Gmbh Derives de pyrimidinone utilises en tant qu'antagonistes de shp2
GB201905328D0 (en) 2019-04-15 2019-05-29 Azeria Therapeutics Ltd Inhibitor compounds
EP3962951A1 (fr) 2019-05-03 2022-03-09 Sutro Biopharma, Inc. Conjugués d'anticorps anti-bcma
GB201908885D0 (en) 2019-06-20 2019-08-07 Storm Therapeutics Ltd Therapeutic compounds
EP4023639A1 (fr) 2019-08-31 2022-07-06 Etern Biopharma (Shanghai) Co., Ltd. Dérivé de pyrazole pour inhibiteur de fgfr et son procédé de préparation
US20220389003A1 (en) 2019-09-20 2022-12-08 Ideaya Biosciences, Inc. 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors
GB201913988D0 (en) 2019-09-27 2019-11-13 Celleron Therapeutics Ltd Novel treatment
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915829D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
US20230116403A1 (en) 2019-12-02 2023-04-13 Storm Therapeutics Limited Polyheterocyclic compounds as mettl3 inhibitors
WO2021155006A1 (fr) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
GB202004960D0 (en) 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
GB202012969D0 (en) 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds
US20230391770A1 (en) 2020-10-06 2023-12-07 Storm Therapeutics Limited Mettl3 inhibitory compounds
WO2022074391A1 (fr) 2020-10-08 2022-04-14 Storm Therapeutics Limited Composés inhibiteurs de mettl3
EP3992191A1 (fr) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Dérivés d'imidazo[4,5-c]quinoline et leur utilisation en tant qu'inhibiteurs de kinase atm
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2022197641A1 (fr) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. Dérivés de 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine servant de modulateurs et/ou d'inhibiteurs de kinase progénitrice hématopoïétique 1 (hpk1) pour traiter le cancer et d'autres maladies
CN117396231A (zh) 2021-04-30 2024-01-12 新基公司 使用抗BCMA抗体药物缀合物（ADC）与γ分泌酶抑制剂（GSI）的组合的组合疗法
CA3218697A1 (fr) 2021-05-03 2022-11-10 Merck Patent Gmbh Conjugues fragment-medicament de liaison a l'antigene fc ciblant her2
JP2024519054A (ja) 2021-05-17 2024-05-08 エイチケイ イノ．エヌ コーポレーション ベンズアミド誘導体、その調製方法、およびそれを有効成分として含む、がんの予防または治療のための医薬組成物
CA3221411A1 (fr) 2021-05-25 2022-12-01 Merck Patent Gmbh Conjugues fragment de liaison a l'antigene fc-medicament ciblant l'egfr
GB202107907D0 (en) 2021-06-02 2021-07-14 Storm Therapeutics Ltd Combination therapies
GB202108383D0 (en) 2021-06-11 2021-07-28 Argonaut Therapeutics Ltd Compounds useful in the treatment or prevention of a prmt5-mediated disorder
WO2023057389A1 (fr) 2021-10-04 2023-04-13 Forx Therapeutics Ag Composés inhibiteurs de parg
WO2023057394A1 (fr) 2021-10-04 2023-04-13 Forx Therapeutics Ag Dérivés de n,n-diméthyl-4-(7-(n-(1-méthylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)pipérazine-1-carboxamide et dérivés correspondants de pyrazolo[1,5-a]pyridine utilisés en tant qu'inhibiteurs de parg pour le traitement du cancer
AU2023205435A1 (en) 2022-01-10 2024-08-22 Cancer Research Horizons Substituted heterocycles as hset inhibitors
GB202202199D0 (en) 2022-02-18 2022-04-06 Cancer Research Tech Ltd Compounds
WO2023175184A1 (fr) 2022-03-17 2023-09-21 Forx Therapeutics Ag Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés comme inhibiteurs de parg pour le traitement du cancer
WO2023175185A1 (fr) 2022-03-17 2023-09-21 Forx Therapeutics Ag Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés en tant qu'inhibiteurs de parg pour le traitement du cancer
WO2023186881A1 (fr) 2022-03-29 2023-10-05 Baden-Württemberg Stiftung Ggmbh Inhibiteurs de la map kinase p38 à utiliser dans le traitement du cancer colorectal
GB202204935D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd Nanoparticles
WO2023196432A1 (fr) 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Modulateurs du récepteur de la chimiokine et leurs utilisations
GB202209404D0 (en) 2022-06-27 2022-08-10 Univ Of Sussex Compounds
WO2024006542A1 (fr) 2022-06-30 2024-01-04 Sutro Biopharma, Inc. Anticorps anti-ror1 et conjugués d'anticorps, compositions comprenant des anticorps anti-ror1 ou des conjugués d'anticorps, et méthodes de fabrication et d'utilisation d'anticorps anti-ror1 et de conjugués d'anticorps
WO2024030825A1 (fr) 2022-08-01 2024-02-08 Neupharma, Inc Sels cristallins de sels cristallins de (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-diméthyl-17-(2-oxo-2h-pyran-5-yl)hexadécahydro-1h-cyclopenta[a]phénanthren-3-yl pipérazine-1-carboxylate
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213167D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213166D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2024074497A1 (fr) 2022-10-03 2024-04-11 Forx Therapeutics Ag Composé inhibiteur de parg
WO2024094962A1 (fr) 2022-11-02 2024-05-10 Cancer Research Technology Limited Dérivés de pyrido[2,3-d]pyrimidin-2-amine utilisés en tant qu'inhibiteurs d'egfr pour traiter le cancer
WO2024094963A1 (fr) 2022-11-02 2024-05-10 Cancer Research Technology Limited Dérivés de 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one et de 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1h)-one utilisés en tant qu'inhibiteurs d'egfr pour traiter le cancer
WO2024099898A1 (fr) 2022-11-07 2024-05-16 Merck Patent Gmbh Inhibiteurs de hset bi-et tricycliques substitués
GB202218672D0 (en) 2022-12-12 2023-01-25 Storm Therapeutics Ltd Inhibitory compounds
WO2024153128A1 (fr) 2023-01-18 2024-07-25 Shanghai Antengene Corporation Limited Composés inhibiteurs de prmt5 et leurs utilisations
WO2024173514A1 (fr) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Composés d'imidazopyridine à substitution amide et ester
WO2024173530A1 (fr) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Composés pyrazolo/imidazo pyridine à substitution hétéroaryle
WO2024173524A1 (fr) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Composés benzimidazoles à substitution hétéroaryle
WO2024173453A1 (fr) 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Composés d'imidazopyridine à substitution hétéroaryle

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3266990A (en) * 1963-09-24 1966-08-16 Warner Lambert Pharmaceutical Derivatives of quinazoline
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4343940A (en) * 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
ATE110071T1 (de) * 1988-01-23 1994-09-15 Kyowa Hakko Kogyo Kk Pyridazinon-derivate und diese enthaltende pharmazeutische zubereitungen.
IL89029A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5411963A (en) * 1988-01-29 1995-05-02 Dowelanco Quinazoline derivatives
WO1992014716A1 (fr) * 1991-02-20 1992-09-03 Pfizer Inc. Derives de 2,4-diaminoquinazolines stimulant l'activite anti-tumorale
DE4105518A1 (de) 1991-02-22 1992-08-27 Basf Ag Sulfonylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung
CA2102780C (fr) * 1991-05-10 2007-01-09 Alfred P. Spada Composes de type bis-monoaryle, aryle bicyclique et (ou) heteroaryle inhibant l'activite de tyrosine kinase des recepteurs de l'egf et (ou) du pdgf
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
DE4208254A1 (de) * 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
US5270466A (en) * 1992-06-11 1993-12-14 American Cyanamid Company Substituted quinazoline fungicidal agents
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
DE4309613C2 (de) 1993-03-24 1996-10-17 Bfi Entsorgungstech Vorrichtung zum Verteilen fester Abfallmaterialien auf einem Transportband
GB9314884D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
CA2148082A1 (fr) * 1993-09-03 1995-03-09 Daisuke Machii Derives d'imidazoquinazoline
GB9325217D0 (en) * 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
BR9506936A (pt) * 1994-02-23 1997-09-09 Pfizer Derivados de quinazolina substituídos com 4-heterociclila processos para sua preparaçao e seu uso como agentes anticancerosos
AU2096895A (en) * 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
DK0682027T3 (da) * 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning
TW414798B (en) * 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
DE19503151A1 (de) * 1995-02-01 1996-08-08 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (fr) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
AU5108196A (en) * 1995-03-20 1996-10-08 Dr. Karl Thomae Gmbh Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation
DE69522717T2 (de) * 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
EP0819129B1 (fr) * 1995-04-03 2000-08-02 Novartis AG Derives de pyrazole et leurs procedes de preparation
DE19513330A1 (de) * 1995-04-03 1996-10-10 Schering Ag Neues Verfahren zur Herstellung von Nucleosiden
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
EP0824525B1 (fr) * 1995-04-27 2001-06-13 AstraZeneca AB Derives de quinazoline
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US6020492A (en) * 1995-05-12 2000-02-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
EP0831829B1 (fr) * 1995-06-07 2003-08-20 Pfizer Inc. Derives de pyrimidine heterocycliques a noyaux condenses
JPH11507052A (ja) * 1995-06-07 1999-06-22 スージェン・インコーポレーテッド キナゾリンおよび医薬組成物
IL122855A (en) * 1995-07-06 2004-08-31 Novartis Ag History of N-Phenyl (Alkyl) - 7H-Pyrolo [-3,2d] Pyrimidine - 4 Amine, their preparation and pharmaceutical preparations containing them
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9520822D0 (en) * 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
IL121090A0 (en) * 1995-11-14 1997-11-20 Pharmacia & Upjohn Spa Aryl and heteroaryl purine compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
EP0837063A1 (fr) * 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline

Also Published As

Publication number Publication date
BR9612043A (pt) 1999-12-28
SI0873319T1 (en) 2002-02-28
TW411274B (en) 2000-11-11
TR199801115T2 (xx) 1998-08-21
IL124925A0 (en) 1999-01-26
PT873319E (pt) 2002-01-30
US6362336B1 (en) 2002-03-26
US6258951B1 (en) 2001-07-10
SK282443B6 (sk) 2002-02-05
PL327310A1 (en) 1998-12-07
PL192309B1 (pl) 2006-09-29
GR3036954T3 (en) 2002-01-31
MY132405A (en) 2007-10-31
CZ291100B6 (cs) 2002-12-11
US5962458A (en) 1999-10-05
SK82898A3 (en) 1998-11-04
CZ188298A3 (cs) 1998-09-16
CA2237005C (fr) 2006-03-14
US20020032208A1 (en) 2002-03-14
KR100530311B1 (ko) 2006-03-09
DE69614147T2 (de) 2002-03-21
GB9624482D0 (en) 1997-01-15
HUP9901243A2 (hu) 1999-08-30
EP0873319A1 (fr) 1998-10-28
HUP9901243A3 (en) 2001-11-28
ATE203524T1 (de) 2001-08-15
NZ324007A (en) 1999-11-29
KR20000064455A (ko) 2000-11-06
JP2000515114A (ja) 2000-11-14
AU712370B2 (en) 1999-11-04
WO1997022596A1 (fr) 1997-06-26
NO311358B1 (no) 2001-11-19
NO982784L (no) 1998-08-17
CA2237005A1 (fr) 1997-06-26
DE69614147D1 (de) 2001-08-30
CN1205694A (zh) 1999-01-20
CN1133625C (zh) 2004-01-07
JP4291413B2 (ja) 2009-07-08
AU1106197A (en) 1997-07-14
US6071921A (en) 2000-06-06
NO982784D0 (no) 1998-06-17
EP0873319B1 (fr) 2001-07-25
RU2194701C2 (ru) 2002-12-20
MX9804247A (es) 1998-09-30
ES2162656T3 (es) 2002-01-01

Similar Documents

Publication Publication Date Title
DK0873319T3 (da) Quinazolinderivater
NO991423L (no) Kinolinderivater som inhiberer effekten av vekstfaktorer som VEGF
CA2344290A1 (fr) Derives de quinazoline
CA2263319A1 (fr) Derives quinazolines et compositions pharmaceutiques les contenant
PL328310A1 (en) Derivatives of quinazoline
UA72946C2 (uk) Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
ATE215075T1 (de) Hydroxylamin-derivate mit anti-ischämischer wirkung und pharmazeutische zusammensetzungen diese enthaltend